Citations

Clear

224 citation(s) found for "Su, Jen-Jen".

Clinical utility of expanded screening of the KRAS and NRAS genes for Metastatic Colorectal Cancer: Evaluation of the CRC RAScan tumor test as a companion diagnostic to determine efficacy of anti-EGFR therapies.
Peterson, Stephanie, Bevilacqua, Jen, Veys, Stephanie, Rosendale, Vicki, Legendre, B. L. , Bible, Keith C. , Richardson, Katherine Anne, Peterson, Stephanie, Legendre, Benjamin L., Reddi, Honey V.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e12554-e12554

10.1200/jco.2015.33.15_suppl.e12554 Get It

Quantitative phenotype analysis to identify, validate and compare rat disease models
Zhao, Yiqing , Smith, Jennifer R. , Wang, Shur‐Jen , Dwinell, Melinda R. , Shimoyama, Mary

Mayo Clinic

Database | March 5, 2019 | Volume: 2019 | Issue: No issue available | Pages: No page available

10.1093/database/baz037 | PMID 30938777 Get It

Abstract A17: Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma
Res, HongZheng, Hou, Xiaonan , Pierson, Karlyn E. , Eiken, Patric, Nair, Asha, Yang, PingYang, Yi, Joanne, Jen, Jin , Eiken, Patrick W. , Mansfield, Aaron S.

Mayo Clinic

Clinical Cancer Research | February 4, 2019 | Volume: 24 | Issue: 17_Supplement | Pages: A17-A17

10.1158/1557-3265.aacriaslc18-a17 Get It

Abstract In lung adenocarcinoma, gene fusion involving the anaplastic lymphoma kinase (ALK) gene leads to overexpression of its tyrosine kinase domain, which serves as the oncogenic driver in lung tumors carrying such a molecular alteration. Similar fusions involving ROS1, RET and NTRK are also found in lung cancer and tumors with oncogenic fusions often respond well to targeted therapy. However, these tumors do develop resistance to the targeting drug and patients eventually relapse while on treatment. Although newer drugs have been developed, it remains a challenge to effectively control cancer recurrence after targeted therapy. In vivo tumor models carrying these fusions, particularly those that have progressed while on targeted treatment, will help to facilitate further drug evaluations prior to their administration to the patient as well as offer an opportunity to better understand the molecular mechanisms driving disease onset, progression, and drug resistance in tumors carrying the fusion of interest. Here, we describe the first patient-derived tumor xenograft (PDX) carrying an STRN-ALK fusion. The patient was diagnosed with stage IV lung adenocarcinoma in 2011. She was initially treated with crizotinib and remained stable until 2015. At the time of disease progression, a biopsy was taken with patient consent under CT guidance from a chest wall mass using an 18-gauge needle and then implanted into two SCID-beige mice subcutaneously and into the fat pad of the kidney. Palpable tumor was observed in both mice at about 28 weeks post implantation and passaged at 36 weeks. They have been passaged two successive times and viably frozen. Pathologic analysis of the PDX showed that both tumors have the same mucinous morphology as observed in the original biopsy sample. RNA-seq and matepair analysis revealed that the tumors carry a rare fusion involving the first three exons of STRN and exon 20 to 3’ end of the ALK gene. The patient has been on ceritinib since January 2016 and remains stable as of last follow up. Several unique features contributed to the success of this study. 1) The metastatic chest wall lesion used for the PDX developed was easily accessible on the chest wall using a relative large 18-gauge needle for CT-guided biopsies. 2) The slow growth of the tumor biopsy mirrors the clinical course of the disease observed in the patient. 3) The patient remains clinically stable and continues to respond to TKi. The availability of a viable PDX tumor model for this rare STRN-ALK fusion offers a unique opportunity to identify the most appropriate drug for the patient at the time of disease progression as well as the opportunity to examine the unique molecular features associated with this rare ALK fusion. This work was supported in part by the National Foundation for Cancer Research Hillsberg Lung Cancer Translational Research Grant and by the Biomarker Discovery Program at the Mayo Clinic Center for Individualized Medicine. Citation Format: HongZheng Res, XiaoNan Hou, Karlyn E. Pierson, Patric Eiken, Asha Nair, PingYang Yang, Joanne Eunhee Yi, Aaron S. Mansfield, Jin Jen. Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr A17.
Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
Cho, Yeoungjee , Sautenet, Bénédicte , Gutman, Talia , Rangan, Gopala K. , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Coolican, Helen, Kao, Juliana T‐W, Gansevoort, Ron T. , Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, Claire, Oh, Yun Kyu , Teixeira‐Pinto, Armando , Logeman, Charlotte , Howell, Martin , Ju, Angela, Manera, Karine , Tong, Allison , Torres, Vicente E , Johnson, David W , Howell, Martin , Ong, Albert C M , Ahn, Curie , Kao, Juliana Tze‐Wah , Perrone, Ronald D. , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Cho, Yeoungjee

Mayo Clinic

Nephrology | January 21, 2019 | Volume: 24 | Issue: 12 | Pages: 1214-1224

10.1111/nep.13566 | PMID 30663163 Get It

ABSTRACTAimPatients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient‐centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision‐making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.MethodsNominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0–1) for each outcome and conducted thematic analyses.ResultsAcross 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end‐stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.ConclusionFor patients with ADPKD and their caregivers, kidney function, delayed progression to end‐stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient‐important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Hodi, F. Stephen , Hamid, Omid , Hwu, Wen-Jen, Gangadhar, Tara C., Patnaik, Amita , Dronca, Roxana , Zarour, Hassane M. , Gergich, Kevin, Li, Xiaoyun , Iannone, Robert, Kang, Soonmo Peter, Ebbinghaus, Scot, Ribas, Antoni , Kefford, Richard , Daud, Adil , Wolchok, Jedd D. , Hwu, Wen‐Jen , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Robert, Caroline

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA9000-LBA9000

10.1200/jco.2014.32.15_suppl.lba9000 Get It

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Kefford, Richard , Hamid, Omid , Hodi, F. Stephen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Dolled‐Filhart, Marisa, Lunceford, Jared , Emancipator, Kenneth , Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen‐Jen , Ribas, Antoni , Robert, Caroline , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3005-3005

10.1200/jco.2014.32.15_suppl.3005 Get It

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509 Get It

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Foltz, Lynda, Ritchie, Ellen K. , Silver, Richard T. , Hong, Wan‐Jen , Kremyanskaya, Marina , Trehu, Elizabeth, Verstovšek, Srđan , Mesa, Ruben A. , Gupta, Vikas , Mascarenhas, John , Hoffman, Ronald , Kantarjian, Hagop M. , Gotlib, Jason

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7114-7114

10.1200/jco.2014.32.15_suppl.7114 Get It

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Elassaiss‐Schaap, Jeroen , Hodi, F. Stephen , Hamid, Omid , Hwu, Wen‐Jen , Kefford, Richard , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Joseph, Richard W. , Wolchok, Jedd D. , Joshua, Anthony M. , Ribas, Antoni , Robert, Caroline , Daud, Adil , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3015-3015

10.1200/jco.2014.32.15_suppl.3015 Get It

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Hodi, F. Stephen , Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Perrone, Andrea , Gammage, Linda, Hille, Darcy A., Xue, Dahai, Kang, Soonmo Peter, Chun, Patrick, Ebbinghaus, Scot, Ribas, Antoni , Daud, Adil , Robert, Caroline , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie, Wolchok, Jedd D.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3006-3006

10.1200/jco.2014.32.15_suppl.3006 Get It